Healthcare - Biotechnology - NASDAQ - US
$ 4.49
-7.8 %
$ 3.13 B
Market Cap
-5.41
P/E
Price Target
Average
--100.00%
Revenue Forecast
Estimate
673.94%
EBIT
Estimate
--57.55%
Net Income
Estimate
32.59%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
ImmunityBio, Inc.
IBRX has no price targets from Wall Street.
REVENUE FORECAST
Revenue Forecast Chart IBRX
EBIT FORECAST
EBIT Forecast Chart IBRX
NET INCOME FORECAST
Net Income Chart IBRX